Allogeneic stem cell transplantation for aplastic anemia

被引：47

作者：

Armand, Philippe ^{[1
]}

Antin, Joseph H. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2007年 / 13卷 / 05期

关键词：

aplastic anemia; allogeneic stem cell transplantation; immunosuppressive therapy;

D O I：

10.1016/j.bbmt.2007.02.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aplastic anemia encompasses a heterogeneous group of diseases with distinct pathophysiologies and a common clinical endpoint of marrow failure. Patients with severe aplastic anemia can be treated with immunosuppressive therapy (IST) or hematopoietic stem cell transplantation (HSCT). Over the last 30 years, advances in both treatment modalities have significantly improved the prognosis for this disease; yet this evolution complicates the central therapeutic question in aplastic anemia: which patients should receive IST and which ones should receive HSCT as front-line therapy? In this review, we describe the major improvements that have occurred in transplantation for aplastic anemia in the last 3 decades. We then outline a framework for deciding which patients should be considered for upfront transplantation. (c) 2007 American Society for Blood and Marrow Transplantation.

引用

页码：505 / 516

页数：12

共 105 条

[1] Long-term outcome after bone marrow transplantation for severe aplastic anemia [J].

Ades, L ;

Mary, JY ;

Robin, M ;

Ferry, C ;

Porcher, R ;

Esperou, H ;

Ribaud, P ;

Devergie, A ;

Traineau, R ;

Gluckman, E ;

Socié, G .

BLOOD, 2004, 103 (07) :2490-2497

[2] MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA - LONG-TERM OUTCOME IN 50 UNTRANSFUSED PATIENTS [J].

ANASETTI, C ;

DONEY, KC ;

STORB, R ;

MEYERS, JD ;

FAREWELL, VT ;

BUCKNER, CD ;

APPELBAUM, FR ;

SULLIVAN, KM ;

CLIFT, RA ;

DEEG, HJ ;

FEFER, A ;

MARTIN, PJ ;

SINGER, JW ;

SANDERS, JE ;

STEWART, PS ;

WITHERSPOON, RP ;

THOMAS, ED .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (04) :461-466

[3]

ANTIN JH, 1985, BLOOD, V66, P1247

[4]

Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3

[5] Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia:: a report from the EBMT-SAA Working Party [J].

Bacigalupo, A ;

Locatelli, F ;

Lanino, E ;

Marsh, J ;

Socié, G ;

Maury, S ;

Prete, A ;

Locasciulli, A ;

Cesaro, S ;

Passweg, J .

BONE MARROW TRANSPLANTATION, 2005, 36 (11) :947-950

[6] Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors [J].

Bitan, M. ;

Or, R. ;

Shapira, M. Y. ;

Aker, M. ;

Resnick, I. B. ;

Ackerstein, A. ;

Samuel, S. ;

Elad, S. ;

Slavin, S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (07) :712-718

[7] Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia [J].

Brodsky, RA ;

Sensenbrenner, LL ;

Smith, BD ;

Dorr, D ;

Seaman, PJ ;

Lee, SM ;

Karp, JE ;

Brodsky, I ;

Jones, RJ .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (07) :477-483

[8]

CAMITTA BM, 1976, BLOOD, V48, P63

[9]

CAMITTA BM, 1979, BLOOD, V53, P504

[10]

CASADO JA, 2006, J MED GENET

← 1 2 3 4 5 6 7 8 9 10 →